Beware: Newly recognized heart cardiomyopathy is not always benign

Even though a newly recognized cardiomyopathy, which mainly impacts women, is typically treatable, Tako-tsubo cardiomyopathy can also be deadly when compounded by other co-morbidities, such as heart failure, according to a study being presented March 9 at the American College of Cardiology (ACC) Scientific Sessions.

This condition, formally known as Tako-tsubo (TTC) and informally known as or , has abrupt onset of symptoms and is characterized by a distinctive left ventricular (LV) contraction profile. Ninety percent of the time, this condition affects women, who are usually middle aged and older, and the condition usually is triggered by a .

"Although TTC is typically reversible and considered to have favorable clinical outcomes, we have identified an important subset of patients, particularly those with severe and hypotension, who can have a substantial ," says the study's lead author Scott W. Sharkey, MD, a research cardiologist at the Minneapolis Heart Institute Foundation and a physician at the Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis. "It's also important that physicians are aware this is not a rare a condition, as it is present in nearly 10 percent of women who present to the hospital with suspected heart attacks."

MHIF researchers reviewed 250 TTC patients who presented to the Minneapolis Heart Institute at Abbott Northwestern Hospital between 2001 and 2012. Then, they segregated those TTC patients presenting with particularly severe heart failure and very low pressure, or hypotension ( < 100 mm Hg), who required supportive treatment.

They found that severe hypotensive heart failure occurred in 45 patients. In this subset, 9 female patients died in-hospital despite intervention, representing the only TTC-related hospital deaths in the 250 patient cohort.

Therefore, Sharkey and his colleagues concluded that TTC is not necessarily a benign condition. Severe hypotensive heart failure of severity necessitating vasopressor and/or intra-aortic balloon pump occurs in nearly 20 percent of patients. Also, all TTC-related hospital deaths occurred in the hypotensive heart failure subgroup with an overall mortality of 3.5 percent.

Importantly, triggering physical stressors related to severe co-morbid non-cardiac conditions (8) or advanced age (1) were present in all 9 non-survivors, Sharkey notes.

"Unfortunately, there are not any guidelines or criteria to instruct diagnosis and treatment of these patients at this time," says Sharkey. "Therefore, this study could be a starting point for this process, as it provides a more complete profile of the clinical spectrum of TTC and provides useful guidance for the effective management of these acutely ill patients."

To raise additional awareness and improve care of these patients, he adds that guidelines would be helpful at this time, in order to standardize diagnosis and treatment across varied healthcare settings.

Provided by Minneapolis Heart Institute Foundation

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Are ICDs up to par with patients living longer?

Apr 04, 2011

Most patients with ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM) who have an implantable cardioverter-defibrillator (ICD) now live more than seven years and those ICD patients with hereditary heart disease ...

Cardiac MR sheds light on obscure heart muscle condition

Nov 17, 2010

Left ventricular non-compaction (LVNC), a cardiomyopathy about which little is fully understood, is associated with heart failure (HF), stroke and ventricular arrhythmias, according to a study to be presented Nov. 17 at the ...

Recommended for you

Time to take notice and tackle heart failure

9 hours ago

Experts have sounded a call to action for policy makers at local, national, and international levels to promote heart failure prevention, improve heart failure awareness among healthcare professionals, ensure ...

Hopes dashed for an agent to prevent reperfusion injury

12 hours ago

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective ...

User comments